Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Level V
Where this comes from
- Record sourced from PubMed, PMID 21948230.
- Also identified by DOI 10.1158/1078-0432.CCR-11-2240.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (α), followed by a slow decline (β). The rate of β decrease is consistent with declining leukemic stem cells and may predict which patients may safely discontinue therapy.
Medical subject headings
- Fusion Proteins, bcr-abl
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Neoplastic Stem Cells
- Piperazines
- Pyrimidines